Baxalta Incorporated, (NYSE:BXLT) announced that the Centers for Medicare and Medicaid Services (CMS) have expanded coverage to include in-home use of HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], a treatment for adults with primary immunodeficiency (PI).Baxalta Incorporated (NYSE:BXLT) belongs to Healthcare sector. Its weekly performance is 21.88%. On last trading day company shares ended up $37.10. Baxalta Incorporated (NYSE:BXLT) distance from 50-day simple moving average (SMA50) is 16.62%.
On 29 July, IPC Healthcare, Inc. (NASDAQ:IPCM) reported Adjusted net income for the three months ended June 30, 2015 decreased 6.9% to $9.5 million, or a 5.2% adjusted net income margin, compared with adjusted net income of $10.2 million, or a 5.9% adjusted net income margin, for the same period in the prior year. IPC Healthcare, Inc. (NASDAQ:IPCM) shares increased 35.56% in last trading session and ended the day at $79.25. IPCM Gross Margin is 26.60% and its return on assets is 5.30%. IPC Healthcare, Inc. (NASDAQ:IPCM) quarterly performance is 67.12%.
Abiomed, Inc. (NASDAQ: ABMD), reported first quarter fiscal 2016 revenue of $73.4 million, an increase of 50% compared to revenue of $48.8 million for the same period of fiscal 2015. First quarter fiscal 2016 GAAP net income was $8.9 million or $0.20 per diluted share, compared to GAAP net loss of $1.7 million or a loss of $0.04 per diluted share for the prior year period. On 04 August, ABIOMED, Inc. (NASDAQ:ABMD) shares increased 14.73% and was closed at $88.80. ABMD EPS growth in last 5 year was 48.00%. ABIOMED, Inc. (NASDAQ:ABMD) year to date (YTD) performance is 133.32%.
Luminex Corp (NASDAQ:LMNX) reported second-quarter 2015 adjusted earnings of 22 cents per share, which beat the Zacks Consensus Estimate of 12 cents. Adjusted earnings per share (EPS) also increased 37.5% on a year-over-year basis owing to higher revenues and expanding margins. Luminex Corporation (NASDAQ:LMNX) ended the last trading day at $20.21. Company weekly volatility is calculated as 4.50% and price to cash ratio as 9.16. Luminex Corporation (NASDAQ:LMNX) showed a weekly performance of 13.48%.
Incyte Corporation (NASDAQ:INCY) reported net product revenues of Jakafi were $142 million as compared to $84 million for the same period in 2014, representing 69 percent growth. For the six months ended June 30, 2015, net product revenues of Jakafi were $258 million as compared to $154 million for the same period in 2014, representing 68 percent growth. Incyte Corporation (NASDAQ:INCY) shares increased 5.54% in last trading session and ended the day at $109.74. INCY Gross Margin is 99.00% and its return on assets is -8.50%. Incyte Corporation (NASDAQ:INCY) quarterly performance is 12.55%.